Cancer Vaccine Makers Capitalize On Provenge Fanfare At ASCO
Executive Summary
Heading into this year's American Society of Clinical Oncology meeting, beleaguered cancer immunotherapy developers finally have some cause for optimism about potential partnerships and, battle-hardened, they say they are hearty enough to wait for deals to roll in